trending Market Intelligence /marketintelligence/en/news-insights/trending/7IsEr7Qe37lzGdNuPPyebw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA OKs label update for Novartis' Tasigna with treatment-free remission data

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA OKs label update for Novartis' Tasigna with treatment-free remission data

The U.S. Food and Drug Administration approved the inclusion of treatment-free remission data to the product label for Novartis AG's blood cancer drug Tasigna.

Tasigna is now the first and only BCR-ABL tyrosine kinase inhibitor to include data in its prescribing information about attempting treatment discontinuation in eligible adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase after achieving sustained deep molecular response of MR4.5.

This approval follows a priority review for a supplemental new drug application for Tasigna seeking the addition of the information and is based on safety and efficacy results from analyses of two open label trials where patients achieved a sustained MR4.5 with Tasigna in both the first-line setting or after switching from Glivec.